Evidence Snapshot
What this grade covers
Applies exclusively to Copeptin's DIAGNOSTIC/BIOMARKER evidence dimension — NOT a treatment-efficacy grade, because no Copeptin therapeutic-intervention literature exists. Reflects multiple real, controlled/observational human diagnostic-accuracy studies across distinct clinical contexts (NSTEMI rule-out meta-analysis, PMID 29979797; head-to-head hs-troponin-alone-vs-plus-copeptin rule-out, PMID 36017085; post-pituitary-surgery DI rule-out, PMID 36271992; arginine-stimulation differential diagnosis, PMID 39863827), a genuine and load-bearing negative finding (PMID 36017085's failure to improve on troponin-alone rule-out), and cutoff/specificity heterogeneity across contexts that must not be merged into one universal cutoff. This grade must never be read, cited, or paraphrased as evidence of Copeptin's therapeutic efficacy, which does not exist as a category of evidence for this molecule.
Regulatory Context
Copeptin is a diagnostic biomarker measured by clinical laboratory assay. It is not an FDA-approved therapeutic and no evidence found in this review describes any Copeptin drug product.
Research Takeaway
Copeptin is the stable, ~39-amino-acid C-terminal glycopeptide (CT-proAVP) co-secreted with AVP from the same precursor, used clinically as a stable surrogate marker for AVP secretion rather than as a bioactive hormone in its own right.
See all 7 evidence claims →Quick Summary
Copeptin is a stable, co-secreted fragment of the same precursor that produces Arginine Vasopressin (AVP), used clinically as a diagnostic and prognostic biomarker rather than as a treatment. Its strongest evidence is in ruling out diabetes insipidus after pituitary surgery and in myocardial-infarction rule-out protocols; a major limitation is that adding it to high-sensitivity troponin did not clearly improve rule-out safety over troponin alone in at least one direct comparison.
Mechanism & Research Overview
Copeptin is a stable, co-secreted fragment of the same precursor that produces Arginine Vasopressin (AVP), used clinically as a diagnostic and prognostic biomarker rather than as a treatment. Its strongest evidence is in ruling out diabetes insipidus after pituitary surgery and in myocardial-infarction rule-out protocols; a major limitation is that adding it to high-sensitivity troponin did not clearly improve rule-out safety over troponin alone in at least one direct comparison.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Copeptin is the stable, ~39-amino-acid C-terminal glycopeptide (CT-proAVP) co-secreted with AVP from the same precursor, used clinically as a stable surrogate marker for AVP secretion rather than as a bioactive hormone in its own right.
Supported
Adding Copeptin to cardiac troponin measurement improves sensitivity and negative predictive value for ruling out NSTEMI compared with troponin alone, across a meta-analysis of 14 observational studies.
Supported
In a head-to-head comparison at very low cutoffs, adding ultra-sensitive Copeptin to high-sensitivity troponin I did not meaningfully improve the safety of instant AMI rule-out over troponin I alone.
Does not establish
Evidence boundary: A negative comparative finding in one protocol does not invalidate Copeptin's utility in other validated protocols/cutoffs; results are cutoff- and protocol-specific.
Supported
Postoperative Copeptin measurement (day 1, cutoff >3.4 pmol/L) is a validated rule-out test for diabetes insipidus after pituitary surgery, with high sensitivity and negative predictive value in a 78-patient single-center cohort.
Does not establish
Evidence boundary: Cutoff and performance figures are specific to this cohort/assay and must not be treated as a universal cutoff without validation elsewhere.
Sources: Post-pituitary surgery copeptin analysis as a 'rule-out' test for post-operative diabetes insipidus
Supported
Arginine-stimulated Copeptin response differentiates AVP-deficiency (central diabetes insipidus) from primary polydipsia and healthy adults; the arginine-associated rise in plasma urea is only weakly correlated with the Copeptin response, arguing against urea as the principal driver of the test's diagnostic signal.
Supported
No controlled human Copeptin administration or intervention study was identified in the search conducted for this review; Copeptin is used exclusively as a diagnostic/prognostic biomarker, never as an administered treatment, in every source found.
Supported
Elevated Copeptin is a nonspecific stress marker also raised in sepsis, pneumonia, acute pancreatitis, and acute aortic syndromes; an elevated result reflects prognostic association with worse outcomes in these settings, not a causal or treatable target.
Does not establish
Evidence boundary: Prognostic association must not be rewritten as 'lowering Copeptin improves outcomes' — no interventional evidence supports that inference.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Copeptin rises nonspecifically with physiologic stress, illness severity, and possibly renal function/age, independent of the specific condition being tested for; modest specificity was reported in the post-pituitary-surgery rule-out cohort (55% per secondary summaries, not independently re-derived here).Safety Consideration
Elevated Copeptin's association with worse outcomes in acute illness must not be read as identifying a modifiable/treatable target.Safety Consideration
Diagnostic cutoffs and performance figures are assay- and protocol-specific (NSTEMI vs. DI vs. AVP-deficiency differential) and must not be merged across contexts.
Research Areas Being Studied
Research areas discussed on this page reflect the Renal / Fluid-Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Relationship between plasma urea and copeptin in response to arginine stimulation in healthy adults, patients with vasopressin deficiency and primary polydipsia (2025):
- Post-pituitary surgery copeptin analysis as a 'rule-out' test for post-operative diabetes insipidus (2022):
- Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis (2018):
- High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Relationship between plasma urea and copeptin in response to arginine stimulation in healthy adults, patients with vasopressin deficiency and primary polydipsia | 2025 | N=30 healthy adults, 69 AVP-deficiency patients, 89 primary polydipsia patients | Copeptin rises substantially by 60 minutes post-arginine in healthy adults/primary polydipsia but remains flat in AVP-deficiency patients; the arginine-associated rise in plasma urea only weakly correlates with the copeptin response (r=0.01-0.28), arguing against urea as the principal driver of the test's diagnostic signal. | ||
| Post-pituitary surgery copeptin analysis as a 'rule-out' test for post-operative diabetes insipidus | 2022 | N=78, single-center UK cohort | Copeptin >3.4 pmol/L at postoperative day 1 achieved 91% sensitivity and high negative predictive value for ruling out diabetes insipidus after pituitary surgery; specificity was more modest (approximately 55% per secondary summaries, not independently re-derived from the primary paper's own tables). | ||
| Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis | 2018 | Meta-analysis of 14 observational studies, N=7,998 | Adding copeptin to cardiac troponin improved sensitivity and negative predictive value for NSTEMI rule-out versus troponin alone. | ||
| High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction | Dual-marker (hs-troponin I + copeptin) and single-marker (hs-troponin I alone) rule-out pathways yielded similar negative predictive value (97.4% vs 98.7%) — copeptin did not meaningfully improve safety of instant rule-out over troponin alone at the studied cutoffs. | Negative/limiting finding: adding copeptin did not improve on troponin-alone rule-out at very low cutoffs in this comparison. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| V1B receptor antagonist patent literature (Copeptin-selection context) | A vasopressin V1B-receptor antagonist patent describing use in patients with an elevated AVP level and/or elevated Copeptin level uses Copeptin only as a diagnostic patient-selection variable, not as an administered agent — supporting the absence of any Copeptin-as-treatment literature. | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published diagnostic-accuracy and biomarker research about Copeptin and does not provide medical advice, a diagnosis, or an individualized testing recommendation.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Copeptin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.